RxSight, Inc. (NASDAQ:RXST) Stake Boosted by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc raised its position in RxSight, Inc. (NASDAQ:RXST - Free Report) by 26.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 132,884 shares of the company's stock after purchasing an additional 27,913 shares during the period. Ensign Peak Advisors Inc owned about 0.33% of RxSight worth $4,569,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Private Trust Co. NA purchased a new position in shares of RxSight during the 4th quarter worth about $34,000. Coppell Advisory Solutions LLC lifted its holdings in shares of RxSight by 108.9% during the 4th quarter. Coppell Advisory Solutions LLC now owns 1,289 shares of the company's stock worth $44,000 after acquiring an additional 672 shares during the period. Arcadia Investment Management Corp MI purchased a new position in shares of RxSight during the 4th quarter worth about $46,000. Harbor Investment Advisory LLC purchased a new position in shares of RxSight during the 4th quarter worth about $52,000. Finally, Global Retirement Partners LLC purchased a new position in shares of RxSight during the 4th quarter worth about $69,000. 78.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at RxSight

In other news, Director Tamara Fountain sold 7,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total transaction of $179,970.00. Following the completion of the sale, the director now owns 24,793 shares of the company's stock, valued at approximately $637,428.03. This trade represents a 22.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.36% of the stock is owned by corporate insiders.

RxSight Price Performance

NASDAQ RXST traded up $0.88 during mid-day trading on Friday, hitting $14.19. The company's stock had a trading volume of 862,724 shares, compared to its average volume of 673,976. RxSight, Inc. has a 52-week low of $12.53 and a 52-week high of $64.50. The stock's fifty day simple moving average is $18.08 and its two-hundred day simple moving average is $30.10. The firm has a market capitalization of $576.64 million, a P/E ratio of -17.10 and a beta of 1.32.

RxSight (NASDAQ:RXST - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The company had revenue of $37.90 million during the quarter, compared to the consensus estimate of $38.74 million. During the same quarter last year, the company earned ($0.25) earnings per share. RxSight's revenue for the quarter was up 28.5% on a year-over-year basis. On average, equities analysts forecast that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on RXST. JPMorgan Chase & Co. reiterated an "underweight" rating and set a $17.00 price objective (down from $40.00) on shares of RxSight in a report on Friday, April 4th. UBS Group lowered shares of RxSight from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $45.00 to $16.00 in a report on Wednesday, April 9th. Piper Sandler began coverage on shares of RxSight in a report on Tuesday, April 15th. They set a "neutral" rating and a $18.00 price objective on the stock. Stifel Nicolaus cut their price objective on shares of RxSight from $33.00 to $28.00 and set a "hold" rating on the stock in a report on Wednesday, March 19th. Finally, Wells Fargo & Company cut their price target on shares of RxSight from $35.00 to $22.00 and set an "equal weight" rating on the stock in a report on Thursday, April 3rd. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $37.60.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.